Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

OUS Approvals Analysis: Expanded CoreValve Indication And Zika IVDs Among August’s CE Marks

Sep 14 2016

• By Reed Miller

Related Content

Expanded Indication For Edwards’ Sapien 3 Squarely In Sight

Apr 06 2016

Data And More Data Expected To Drive BTG Towards Triple-Growth Target

Dec 31 2015

Neuro Medtech Investors Have Time (And Money) For The Pain

Nov 11 2015

APPROVALS ANALYSIS: Big Jump In CE Marks, But Slow August For PMAs

Sep 17 2015

Zika Assay Reviews Are Testing The Limits Of FDA Capacity, Shuren Says

Sep 12 2016

BTG snaps up Biocompatibles

Nov 19 2010

US FDA Approves First Intermediate-Risk Indication For TAVR

Aug 18 2016

Related Companies

Edwards Lifesciences Corp.

BTG plc

Boston Scientific Corporation

Nordion

ViewRay, Inc.

Additional Topics

Asia Pacific Europe Commercial Approvals Research & Development Companies Innovation Medical Device

More from Approvals

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.